Alpha-1-antitrypsin Deficiency: Biology, Diagnosis, Clinical Significance, and Emerging Therapies
Autor Noor Kalsheker, Robert Andrew Stockleyen Limba Engleză Paperback – 7 iun 2017
The book covers the disease from basic biology and epidemiology, to clinical impact, and includes the understanding of the natural history of the disease and the significant advances that have been made in the last 20 years, including the three-dimensional structure of the molecule, its broad biological activity and improved therapeutic options, including replacement therapy and gene therapy.
The editors have recruited international experts in the field to contribute evidence-based chapters and insights on future developments in the understanding of this disease.
- Provides documentation of the variations in clinical presentation and pathology in a single reference
- Presents new insights by pulling together the advances in the understanding of the structure and function of alpha1-antitrypsin deficiency with the genetic variants that cause the disease
- Allows for easy reference for the diagnosis of AATD to lead to better therapeutics
Preț: 711.41 lei
Preț vechi: 962.42 lei
-26% Nou
Puncte Express: 1067
Preț estimativ în valută:
136.15€ • 143.64$ • 113.46£
136.15€ • 143.64$ • 113.46£
Carte tipărită la comandă
Livrare economică 26 decembrie 24 - 09 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128039427
ISBN-10: 0128039426
Pagini: 262
Dimensiuni: 152 x 229 x 17 mm
Greutate: 0.36 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128039426
Pagini: 262
Dimensiuni: 152 x 229 x 17 mm
Greutate: 0.36 kg
Editura: ELSEVIER SCIENCE
Cuprins
1. Historical perspective2. The Swedish AAT screening study: What we have learnt-from birth through to young middle age3. Gene regulation4. AAT variants5. AAT structure and function6. Novel biological functions of A1AT7. AATD and lung disease8. Alpha-1-Antitrypsin Deficiency Liver Disease9. AATD epidemiological studies and other AATD associated diseases10. THORACIC CT IMAGING IN AATD11. Animal models of alpha-1 antitrypsin deficiency12. Establishing European Registries for AATD and clinical trials for lung disease13. Establishing the USA Registry: logistics, impact and early clinical trials14. Gene therapy15. The future of AAT research